Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scienture Holdings, Inc. (SCNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SCNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.97% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 |
52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5392.75% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 21.83 | Enterprise Value 29263103 | Price to Sales(TTM) - |
Enterprise Value 29263103 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 4.11 | Enterprise Value to EBITDA -1.56 | Shares Outstanding 8605370 | Shares Floating 4401989 |
Shares Outstanding 8605370 | Shares Floating 4401989 | ||
Percent Insiders 51.79 | Percent Institutions 1.85 |
Upturn AI SWOT
Scienture Holdings, Inc.
Company Overview
History and Background
I am an AI and do not have real-time access to specific information, including the history of a company called Scienture Holdings, Inc. You will need to research this information from credible sources.
Core Business Areas
- Segment Name 1: I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc., therefore I cannot accurately complete these sections.
- Segment Name 2: I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc., therefore I cannot accurately complete these sections.
Leadership and Structure
I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc.'s leadership or organizational structure. You will need to research this information from credible sources.
Top Products and Market Share
Key Offerings
- Product Name 1: I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc., therefore I cannot accurately complete these sections.
- Product Name 2: I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc., therefore I cannot accurately complete these sections.
Market Dynamics
Industry Overview
I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc. and the specific market it operates in; therefore, I cannot accurately complete these sections.
Positioning
I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc.'s market positioning; therefore, I cannot accurately complete these sections.
Total Addressable Market (TAM)
I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc.'s total addressable market (TAM). Therefore, I cannot accurately complete these sections.
Upturn SWOT Analysis
Strengths
- Requires company specific data
Weaknesses
- Requires company specific data
Opportunities
- Requires company specific data
Threats
- Requires company specific data
Competitors and Market Share
Key Competitors
- Requires company specific data
Competitive Landscape
Requires company specific data
Growth Trajectory and Initiatives
Historical Growth: Requires financial data specific to Scienture Holdings, Inc.
Future Projections: Requires financial data specific to Scienture Holdings, Inc. and analyst estimates.
Recent Initiatives: Requires company specific data about Scienture Holdings, Inc.
Summary
I am an AI and do not have real-time access to specific information about Scienture Holdings, Inc.; therefore, I cannot generate a summary.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information. No financial or other advice is given or implied. Seek an expert.
Disclaimers:
This analysis is based on limited information and should not be considered financial advice. The user should conduct their own due diligence and consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scienture Holdings, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2010-04-27 | Founder, Co-CEO & Executive Chairman Dr. Shankar Hariharan Ph.D. | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 14 | Website https://scienture.com |
Full time employees 14 | Website https://scienture.com | ||
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.